Phytopharm surges on weight-loss drug success
The extract is derived from the African Hoodia cactus, which the San bushmen of the Kalahari desert have been eating for thousands of years to stave off hunger during long hunting trips. The cactus contains a molecule that fools the brain into believing the stomach is full. The licence for the molecule, discovered by South African scientists, was sold in 1997 to Phytopharm, which teamed up with Unilever to conduct safety and efficacy studies and bring the weight-loss product to market.
The yet-to-be-named treatment is expected to be launched in 2008, after first-stage tests showed it is commercially viable to produce the extract. Phytopharm and Unilever are embarking on clinical trials in the second stage of the project to make sure it works on humans and is safe to use. At the same time, Unilever is running a separate agronomy programme to determine whether the cactus, which takes 50 years to reach maturity, can be grown commercially.
As part of the 2004 co-operation agreement between the two companies, Unilever committed to an initial payment of £6.5m for the first stage and has now committed a further £3.5m out of a total of up to £21m in payments to Phytopharm. In addition Phytopharm will receive an undisclosed royalty on sales of all products containing the extract.
Richard Dixey, the chief executive of Phytopharm, said: "Our partnership with Unilever provides a fully funded programme and we look forward to generating royalty income from our partner's globally recognised brands."
After the clinical trials, expected to take a year, Unilever will work on the branding and marketing of the product. The consumer giant pumps €1bn (£694m) into research and development each year, the bulk of which is spent on developing "look good, feel good" products such as antioxidants in tea and appetite suppressants.
In January, Phytopharm struck a deal to license its skin treatment for dogs to Schering-Plough's animal health unit, with expected annual sales of up to $40m (£23m). The news on both treatments has given a welcome boost to Phytopharm, which suffered a setback in November when its Alzheimer's drug failed to show benefits in tests. Phytopharm shares closed up 4p at 43p.
Harry Potter actor suffered 'severe flu-like symptoms' on a flight from London to Orlando
First full-length look is finally here
World cities ranked in terms of safety, food security and 'liveability'
- 2 The awkward moment Sarah Palin raised $25,000 for Hillary Clinton's election campaign
- 3 Ball pool for adults opens in London
- 4 Amal Clooney gives excellent response to fashion question at European Court of Human Rights
- 5 Baldness could soon be treated using stem cells, scientists hope
Woman falls to her death as she celebrates marriage proposal at the edge of Ibiza cliff
Sex abuse inquiry: 'Victims receive death threats' after MPs release names online
Saudi preacher who 'raped and tortured' his five -year-old daughter to death is released after paying 'blood money'
Teenager brandishing fake gun taken down by police after demanding airtime on Netherlands' NOS TV station
The awkward moment Sarah Palin raised $25,000 for Hillary Clinton's election campaign
9 reasons Greece's experiment with the radical left is doomed to failure
'We would evict Queen from Buckingham Palace and allocate her council house,' say Greens
Have we reached 'peak food'? Shortages loom as global production rates slow
Greece elections: Syriza and EU on collision course after election win for left-wing party
British grandmother Lindsay Sandiford faces execution by firing squad in Indonesia
Liberal Democrat minister defends comments suggesting immigration causes pub closures
iJobs Money & Business
£30000 - £35000 per annum + Benefits: Ashdown Group: Marketing Manager - Marke...
£13000 per annum: Recruitment Genius: This Pension Specialist was established ...
£23000 - £26000 per annum + Benefits: Ashdown Group: Market Research Executive...
£25000 - £35000 per annum: Recruitment Genius: A Technical Report Writer is re...